Philadelphia Group Confirms GenoMed's Approach to Pancreatic Cancer.

ST. LOUIS -- GenoMed[TM] (Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health[TM], announced today that its published approach to cancer has recently received support from a group at Thomas Jefferson University in Philadelphia.

Dr. Hwyda Arafat at the Kimmel Cancer Center at Thomas Jefferson University recently showed that angiotensin I-converting enzyme (ACE) was active in tumors from patients with pancreatic cancer, and that ACE inhibitors and angiotensin II receptor blockers (ARBs) blocked the production of a potent angiogenesis factor called VEGF in pancreatic cancer cell lines. She suggested that ACE inhibitors and ARBs might be useful in treating pancreatic cancer patients.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our work, published four years ago, demonstrated that ACE inhibitors and ARBs may work against all but a few cancers. In fact, two years ago we published a case report of a woman with stage IV unresectable pancreatic cancer who lived an extra 14 months using our approach."

Added Dr. Moskowitz, "We're delighted for others to confirm our work again, but if people with cancer, sickle cell disease, viral disease, high blood pressure, diabetes, kidney failure, or emphysema only knew about us, we might be able to help save their lives. At this point, as with the rest of our treatments, the only element missing is public awareness."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.